Octyl itaconate inhibits osteoclastogenesis by suppressing Hrd1 and activating Nrf2 signaling. Issue 11 (6th September 2019)

• Record Type: Journal Article
• Authors: Sun, Xuewu; Zhang, Boya; Pan, Xin; Huang, Hai; Xie, Ziang; Ma, Yan; Hu, Bin; Wang, Jiying; Chen, Zhijun; Shi, Peihua
• Is Part Of: FASEB journal. Volume 33:Issue 11(2019)
• Page Start: 12929
• Page End: 12940
• Publication Date: 2019-09-06
• Subjects: osteoporosis -- osteoclast -- metabolite; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201900887RR
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract : The endogenous metabolite itaconate has emerged as a regulator of macrophage function that limits inflammation. However, its effect on cell differentiation and osteoclast‐related diseases is unclear. Here, for the first time, we explored the effect of itaconate and its cell‐permeable itaconate derivative, 4‐octyl itaconate (OI) on osteoclast differentiation in vitro and in vivo . Firstly, we demonstrated that itaconate concentration was lower in estrogen‐deficient mice. OI released itaconate and induced the expression of nuclear factor–erythroid 2–related factor 2 (Nrf2) in bone marrow–derived macrophages during osteoclastogenesis. Furthermore, OI significantly suppressed the early, middle, and late stages of osteoclastogenesis induced by receptor activator of NF‐αB ligand in vitro, as confirmed by tartrate‐resistant acid phosphatase staining. Moreover, it significantly inhibited fibrous actin ring formation and bone resorption in vitro . Mechanistically, we observed that OI enhanced Nrf2 expression by suppressing its association with ubiquitin via inhibition of the E3 ubiquitin ligase (Hrd1). OI also inhibited LPS‐induced the reactive oxygen species and inflammatory responses via Hrd1. An estrogen deficiency ( via ovariectomy)–induced osteoporosis model was also established. Here, on micro‐computed tomography and histologic analysis showed that OI effectively suppressed ovariectomy‐induced bone loss. In summary, OI, an itaconate derivative, can inhibit osteoclastogenesis in vitro and in vivo, indicating that OI could be a potential drug to treat osteoclast‐related diseases; our results also link itaconate to the development of osteoporosis.—Sun, X., Zhang, B., Pan, X., Huang, H., Xie, Z., Ma, Y., Hu, B., Wang, J., Chen, Z., Shi, P. Octyl itaconate inhibits osteoclastogenesis by suppressing Hrd1 and activating Nrf2 signaling. FASEB J. 33, 12929–12940 (2019). www.fasebj.org